Orthobiologics company goes public

Bone Biologics, which focuses on spinal orthobiologics, announced its underwritten public offering for $5.1 million total.

Advertisement

The company priced 3.7 million units of securities at $1.35 per share, according to an Oct. 7 news release.

Bone Biologics also granted underwriters the option to purchase up to 566,666 additional shares of common stock.

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Is ambulatory care healthcare’s big margin engine? 4 leaders weigh in

Wednesday, July 29
1:00 PM - 2:00 PM CDT

Presenters: Joe Ganley, athenahealthJeffrey Flynn, CASC, Gramercy Surgery CenterBryan Tsao, Access Center, Loma Linda University HealthJason Zepeda, Northridge Hospital Medical Center, CommonSpirit HealthGreg DeConciliis, PA-C, CASC, Boston Out­Patient Surgical Suites

Advertisement

Next Up in Biologics

Advertisement

Comments are closed.